The essential feature of FBLD is that the start- ing point for discovery is a small (MM < 250 Da) compound, with binding usually detected by a bio- physical method; subsequent, usually structure‐ guided, evolution of the fragment generates a hit compound that registers in an assay and can be opti- mized by conventional (predominantly structure‐ guided) medicinal chemistry.